From Casetext: Smarter Legal Research

Novo Nordisk Inc. v. Paddock Labs. Inc.

United States Court of Appeals for the federal Circuit
Dec 19, 2011
468 F. App'x 961 (Fed. Cir. 2011)

Opinion

2012-1031

12-19-2011

NOVO NORDISK INC. AND NOVO NORDISK A/S, Plaintiffs-Appellants, v. PADDOCK LABORATORIES, INC., Defendant-Appellee.


NOTE: This order is nonprecedential.


Appeal from the United States District Court for the District of Minnesota in case no. 10-CV-2199, Judge Donovan W. Frank.


ON MOTION


Before LLNN, Circuit Judge.


ORDER

Paddock Laboratories, Inc. moves for summary affirmance of the United States District Court for the District of Minnesota's judgment on the pleadings in favor of Paddock on Novo Nordisk, Inc. and Novo Nordisk A/S's (collectively "Novo") patent infringement claim. Novo opposes, and moves to "coordinate" this appeal with Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd., Appeal No. 2011-1223. Novo also moves to stay the present appeal pending the Supreme Court's decision in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nord-isk A/S, No. 10-844. Paddock opposes these motions by Novo, and further presents a "cross-motion" in the alternative to lift this court's stay of Appeal No. 2011-1223 pending the Supreme Court's disposition of Caraco.

Appeal No. 2011-1223 is from a decision by the United States District Court for the Eastern District of Michigan involving the same patent as the present appeal. The Minnesota district court, in the judgment from which the present appeal is taken, gave collateral estoppel effect to the Michigan district court's judgments of invalidity as to claim 4 of the asserted patent and unenforceability and entered a judgment on the pleadings in favor of Paddock with respect to these issues.

The Supreme Court heard oral argument in Caraco on December 5, 2011.

Paddock is not a party to Appeal No. 2011-1223.
--------

We deem it the better course to stay the present appeal pending the Supreme Court's disposition of Caraco.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) Paddock's motion for summary affirmance is denied without prejudice.
(2) Novo's motion is granted to the extent that this appeal is stayed pending the disposition of Caraco. The parties are directed to inform this court, within 14 days of the Supreme Court's disposition of Caraco, concerning how they believe this appeal should proceed.
(3) Paddock's cross-motion to lift this court's stay of the Appeal No. 2011-1223 is denied.

FOR THE COURT

__________

Jan Horbaly

Clerk
cc: Mark A. Perry, Esq.

Daniel G. Brown, Esq.

s8


Summaries of

Novo Nordisk Inc. v. Paddock Labs. Inc.

United States Court of Appeals for the federal Circuit
Dec 19, 2011
468 F. App'x 961 (Fed. Cir. 2011)
Case details for

Novo Nordisk Inc. v. Paddock Labs. Inc.

Case Details

Full title:NOVO NORDISK INC. AND NOVO NORDISK A/S, Plaintiffs-Appellants, v. PADDOCK…

Court:United States Court of Appeals for the federal Circuit

Date published: Dec 19, 2011

Citations

468 F. App'x 961 (Fed. Cir. 2011)